| Literature DB >> 28678201 |
Cristina Gardini1, Elena Urso2, Marco Guerrini3, René van Herpen4, Pauline de Wit5, Annamaria Naggi6.
Abstract
Danaparoid sodium salt, is the active component of ORGARAN, an anticoagulant and antithrombotic drug constituted of three glycosaminoglycans (GAGs) obtained from porcine intestinal mucosa extracts. Heparan sulfate is the major component, dermatan sulfate and chondroitin sulfate being the minor ones. Currently dermatan sulfate and chondroitin sulfate are quantified by UV detection of their unsaturated disaccharides obtained by enzymatic depolymerization. Due to the complexity of danaparoid biopolymers and the presence of shared components, an orthogonal approach has been applied using more advanced tools and methods. To integrate the analytical profile, 2D heteronuclear single quantum coherence (HSQC) NMR spectroscopy was applied and found effective to identify and quantify GAG component signals as well as those of some process signatures of danaparoid active pharmaceutical ingredient (API) batches. Analyses of components of both API samples and size separated fractions proceeded through the determination and distribution of the molecular weight (Mw) by high performance size exclusion chromatographic triple detector array (HP-SEC-TDA), chain mapping by LC/MS, and mono- (¹H and 13C) and bi-dimensional (HSQC) NMR spectroscopy. Finally, large scale chromatographic isolation and depolymerization of each GAG followed by LC/MS and 2D-NMR analysis, allowed the sequences to be defined and components to be evaluated of each GAG including oxidized residues of hexosamines and uronic acids at the reducing ends.Entities:
Keywords: component quantitative analysis; danaparoid sodium; low molecular weight glycosaminoglycans; orthogonal multi-analytical methods; sequence and compositional investigations
Mesh:
Substances:
Year: 2017 PMID: 28678201 PMCID: PMC6152146 DOI: 10.3390/molecules22071116
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Size-exclusion chromatography profile of a danaparoid sample (CAT272): (a) red—refractive index (mV), blue—viscometer (mV) and green—right-angle laser light scattering (mV) detectors; (b) UV (mV) detector.
Figure 2Example of 1H-NMR spectrum of a danaparoid sample (CAT272): (a) whole spectrum; (b) expansion of the acetyl region.
Figure 3Example of 13C-NMR spectrum of a danaparoid sample (CAT272): (a) anomeric region; (b) ring carbon region. Black: signals attributed to heparan sulfate (HS); Blue signals attributed to chondroitin sulfate (CS) and dermatan sulfate (DS).
Figure 4Example of 2D Heteronuclear Single Quantum Coherence (HSQC) NMR of a danaparoid sample (CAT272): (a) anomeric region; (b) ring region. Black: signals attributed to HS; Blue: signals attributed to DS and CS. Abbreviations in Table S1.
Percentage of glucosamine residues of heparan sulfate (HS) of one danaparoid sample (CAT272). A* corresponds to 3-O,N-sulfated glucosamine according with the abbreviations shown in Table S1.
| A * | ANAc αred | ANAc-(I) | ANAc-(G) | ANAc-ox | ANS αred | ANS βred | ANS-(G) | ANS-(I) | ANS-(I2S) | A6S |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.2 | 0.9 | 0.3 | 23.4 | 4.4 | 1.7 | 0.4 | 11.4 | 19.3 | 33.5 | 48.4 |
“A *” means 3-O,N-sulfated glucosamine according with the abbreviations in Table S1.
Percentage of uronic acid residues and sulfation degree of HS of one danaparoid (CAT272). (Abbreviations are in Table S1.)
| I2S | I-(A6S) | I-(A6OH) | I-(ANAcox) | G-(ANS) | G-(ANAc) | Sulfation Degree |
|---|---|---|---|---|---|---|
| 43.5 | 11.2 | 6.7 | 3.2 | 13.3 | 22.1 | 1.63 |
Sulfate distribution (percentage) of dermatan sulfate (DS) and chondroitin sulfate (CS) of one danaparoid sample (CAT272). (Abbreviations in Table S1.)
| DS | CS | ||
|---|---|---|---|
| I2S | I | G-(GalNAc,4S) | G-(GalNAc,6S) |
| 8.7 | 91.3 | 80.0 | 20.0 |
Figure 5Liquid Chromatography-Mass Spectrometry (LC-MS) profiles: (a) one danaparoid sample CAT272; (b) ChABC danaparoid digestion product CAT469; (c) UV chromatogram at 232 nm of CAT469.
Figure 6Mass spectra of chromatographic peaks * and $, respectively (as labelled in Figure 5b) and corresponding to structures identified by MS/MS fragmentation experiment (data shown in supplementary material Figures S5 and S6): (a) fragment at m/z 466.0501 (z-2; M 934) attributed to ∆U4,2,2(T1); (b) fragment at m/z 524.0541 (z-2; M 1050) attributed to ∆U5,2,2(Ra). The substitution pattern of DS was used.
Figure 7Preparative size exclusion chromatography (SEC) fractionation chromatographic UV 210 nm profile of a danaparoid (CAT277).
Ranges of weight average molecular weight (Mw) and polydispersity (Pd) of SEC fractions of seven danaparoid Active Pharmaceutical Ingredient (API) samples.
| Fractions | Mw (Da) | Pd |
|---|---|---|
| A | 8200–8800 | 1.14–1.17 |
| B | 5300–5700 | 1.06–1.11 |
| C | 4400–4700 | 1.05–1.11 |
Weight average Mw and polydispersity (Pd) of SEC fractions of danaparoid Active Pharmaceutical Ingredient (API) sample CAT277.
| Fractions | A | B | C | D | E | F | G | H | I | L | M | N |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mw (kDa) | 8.2 | 5.4 | 4.4 | 3.9 | 3.3 | 3.0 | 2.8 | 2.5 | 2.3 | 2.1 | 2.1 | 1.9 |
| Pd | 1.17 | 1.06 | 1.06 | 1.04 | 1.05 | 1.06 | 1.05 | 1.05 | 1.05 | 1.04 | 1.04 | 1.01 |
Figure 8Overlapping of normalized Refractive Index (RI) profiles of SEC fractions of a danaparoid sample (CAT277): (a) fractions A–F, range volume 14–24.5 mL; (b) fractions G–N, range volume 20–24.5 mL.
Variation of dermatan sulfate and chondroitin sulfate among SEC fractions of seven API batches by qualitative observation of peculiar HSQC anomeric signals.
| A | B | C | D | E | F | G | H | I | L | M | N | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAT271 | DS | +++ | +++ | +++ | +++ | ++ | ++ | ++ | ++ | + | − | − | − |
| CS | +++ | +++ | +++ | +++ | ++ | ++ | ++ | + | − | − | − | − | |
| CAT272 | DS | +++ | +++ | +++ | +++ | ++ | ++ | ++ | ++ | ++ | − | − | − |
| CS | +++ | +++ | +++ | +++ | ++ | ++ | ++ | + | + | − | − | − | |
| CAT273 | DS | +++ | +++ | ++ | ++ | ++ | ++ | ++ | + | − | − | − | − |
| CS | +++ | +++ | ++ | ++ | ++ | ++ | − | − | − | − | − | − | |
| CAT274 | DS | +++ | +++ | ++ | ++ | ++ | ++ | + | − | − | − | − | − |
| CS | +++ | +++ | ++ | ++ | + | − | − | − | − | − | − | − | |
| CAT275 | DS | +++ | +++ | ++ | ++ | ++ | ++ | + | − | − | − | − | − |
| CS | +++ | +++ | ++ | ++ | + | − | − | − | − | − | − | − | |
| CAT276 | DS | +++ | +++ | ++ | ++ | ++ | + | + | − | − | − | − | − |
| CS | +++ | +++ | ++ | + | − | − | − | − | − | − | − | − | |
| CAT277 | DS | +++ | +++ | +++ | +++ | ++ | ++ | ++ | ++ | + | − | − | − |
| CS | +++ | +++ | +++ | +++ | ++ | ++ | ++ | + | − | − | − | − |
Where ‘−‘ = absent; ‘+’ = traces; ‘++’ = present; ‘+++’ = more present.
Figure 9Structures of oxidized Reducing End (RE) residues compatible with the observed m/z values (the substitution pattern was in accordance with the observed species listed in Table 7).
Figure 10Mass spectrum displaying the different oxidation forms of oligosaccharide U4,5,0 from M1 to M3 derivative: m/z 552.9907 (z-2, M1 1108) identified as U4,5,0 (T1); m/z 537.9860 (z-2, M2 1078) identified as U4,5,0 (T2); m/z 522.9805 (z-2, M3 1048) identified as U4,5,0 (T3).
Figure 11Mass signal at m/z 881.086 (z-2): (a) experimental m/z and isotopic distribution; (b) theoretical m/z and isotopic distribution corresponding to the regular structure of U6,6,3 (sum formula C42N3O52H65S6); (c) theoretical m/z and isotopic distribution corresponding to the oxidized structure U6,6,3(T4) (sum formula C41N3O53H61S6).
Main species detected in fractions A–N of 7 API samples.
| Fraction | Main Species in the Woul Fraction | GAG | Species Detect at the Top of the Fraction (Pilot Study) |
|---|---|---|---|
| A | A19,10,10(T1) to A27,14,14(T1); A20,10,10(Ra) to A26,13,13(Ra) | CS/DS | - |
| B | A17,9,9(T1) to A21,11,11(T1); A16,8,8(Ra) to A22,11,11(Ra) | CS/DS | - |
| C | A13,7,7(T1) to A15,11,8(T1); A14,7,7(Ra) to A18,9,9(Ra) | CS/DS | - |
| D | U10,9,3 to U10,10,3; A7,10,0(T1); A11,10,6(T1) to A11,11,6(T1); U10,10,3(T1) to U10,13,3(T1) | HS | - |
| E | U8,8,3(T1) to U8,10,3(T1); A11,8,2(T1) to A11,14,2(T1) | HS | U8,10,2(T1); A11,14,1(T1) |
| F | U10,6,2(T1) to U10,8,2(T1); U10,8,1(T1) to U10,13,1(T1) | HS | U7,8,1(T5) to U7,10,1(T5); U10,8,0(T5) |
| G | A9,4,2(T1) # to A9,8,2(T1); A9,8,1(T1) to A9,13,1(T1) | HS | - |
| H | U8,6,1(T1) to U8,10,1(T1); U6,6,3(T4) to U6,8,3(T4) | HS | A9,6,2; A9,9,1 and A9,10,1; U8,6,0(T5) |
| I | A7,6,1 and A7,7,1; A7,5,1(T1) to A7,10,1(T1); U6,4,1 to U6,5,1; U6,6,1(T1) | HS | A7,5,2(T1); U7,4,0(T5) |
| L | A7,6,1; A5,5,1; A7,5,2 # to A7,6,2; U6,5,1(T1) to U6,7,1(T1); U6,6,1(T5) # | HS | U6,3,0(T5) and U6,4,0(T5); A7,7,1; A7,8,0 to A7,9,0; A7,9,1 |
| M | A5,4,1; U6,5,1 to U6,6,1; U6,6,0 to U6,9,0; A5,4,1(T1) to A5,7,1(T1); A5,7,0(T1) | HS | A5,8,1(T1) |
| N | A5,5,0 to A5,9,0; A5,5,1 and A5,6,1; A5,5,1(T1); U4,5,0(T3) | HS | U4,5,0(T1); U4,5,0(T2) |
# species not detected in one sample.
Figure 12Example of structures detected in SEC fractions, the modified RE are highlighted in the boxes: HS sequences are displayed in the upper panel with the terminal T1 at the RE and with the uronic acid or the glucosamine at the non reducing end (NRE) in even or odd oligomers, respectively. CS/DS structures are shown in the lower panel (the substitution pattern of DS is used as example because it is more abundant than CS): two possibly reducing ends are T1 and Ra, the galactosamine is placed at the NRE.
Figure 13Refractive Index profile overlay of a danaparoid sample (CAT272 in green), its enriched CS/DS (red) and HS (blue) fractions.
Figure 14HSQC NMR spectra of CS/DS (a) and HS (b) fraction of danaparoid CAT272. Signals belonging to CS/DS are circled in red.
Figure 15Superimposition of HSQC spectra (C2 region) of a danaparoid sample (CAT272 in blue), its enriched HS (red) and CS/DS fractions (green).
Figure 16LC-MS profiles comparison: (a) danaparoid sample CAT272; (b) CS/DS isolated from CAT271; (c) CS/DS isolated from CAT272; (d) CS/DS isolated from CAT275.
Figure 17LC-MS profiles comparison: (a) danaparoid sample CAT272; (b) HS isolated from CAT271; (c) HS isolated from CAT272; (d) HS isolated from CAT275.
Figure 18LC-MS profiles of HS danaparoid (CAT272), nadroparin and heparin digested by heparinases I, II, III.
Ratio percentage between disaccharides N-acetylated and N-sulfated.
| Sample | Ratio % N-acetylated/N-sulfated Disaccharides |
|---|---|
| HS-CAT271 | 41.4 |
| HS-CAT272 | 39.0 |
| HS-CAT275 | 39.2 |
| nadroparin | 16.8 |
| heparin | 13.2 |